Compositions and methods for inhibiting toll-like receptor 4 mediated inflammation
Synthetic peptides targeting TLR4 inhibit its signaling activity, addressing the lack of effective TLR4 modulation in therapeutic strategies, providing a novel approach to treat inflammatory and autoimmune disorders.
Patent Information
- Application Number
- PCT/US2026/026783
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-05
- Filing Date
- 2026-05-05
- Publication Date
- 2026-11-12
AI Technical Summary
Current therapeutic strategies lack effective means to modulate Toll-like receptor 4 (TLR4) signaling, particularly for treating and preventing diseases associated with aberrant TLR4 activation, such as sepsis, autoimmune disorders, and inflammatory conditions, due to the limited availability of chemical scaffolds and unsatisfactory binding affinities of existing peptide-based TLR4 ligands.
Development of synthetic peptides with specific amino acid sequences that bind to TLR4, inhibiting its signaling activity, and delivery methods using vectors like AAV to target TLR4 within all cellular compartments, providing sustained regulation of inflammation.
The synthetic peptides effectively inhibit TLR4 signaling, reducing inflammatory responses in diseases like sepsis and autoimmune disorders, offering a unique class of molecular agents that can target TLR4 across all cellular membranes without the limitations of existing chemical probes.
Smart Images

Figure IMGF000031_0001_TABLE 
Figure IMGF000038_0001_TABLE 
Figure 00000047_0000
Abstract
Description
COMPOSITIONS AND METHODS FOR INHIBITING TOLL-LIKE RECEPTOR 4 MEDIATED INFLAMMATIONCROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The subject patent application claims the benefit of priority to U.S.Provisional Patent Application Number 63 / 799,795 (filed May 5, 2025; now pending). The full disclosure of the priority application is incorporated herein by reference in its entirety and for all purposes.SEQUENCE LISTING
[0002] This application includes by incorporation of reference a sequence listing in the XML format, 2288_lPC_Sequence_Listing, which was created on May 5, 2026 and contains 20 KB in content.BACKGROUND OF THE INVENTION
[0003] Toll-like receptors (TLRs) precisely coordinate the transmission of extracellular signals across the cell membrane yet harnessing the mechanisms governing their regulation remain a challenge for therapeutic development. Among this family of receptors, Toll-like receptor 4 (TLR4) is best known for its role in detecting bacterial pathogens and triggering an innate immune response through pro-inflammatory pathways. TLR4 is stimulated by LPS, the major pro-inflammatory component of gram-negative bacteria. LPS causes much of its morbidity and mortality by activating kinases that control the function of transcription factors (e.g., NFKB, AP-1 and IRF transcription factors) and ultimately lead to production of proinflammatory cytokines and costimulatory molecules.
[0004] Beyond infection, TLR4 signaling is critically implicated in diseases such as sepsis, allergies, and colitis, where dysregulation presents a key target for intervention. Additionally, therapeutic strategies for cancers and autoimmune disorders leverage TLR4 modulation. Despite its central role in immunity and disease, there are fewchemical scaffolds outside of toxins and lipid derivatives available which target TLR4, especially antagonist for anti-inflammatory modulation.
[0005] There is a need in the art for better means to modulate TLR4 signaling, and for methods to treat and prevent diseases and medical conditions that are associated with or mediated by aberrant TLR4 signaling. The present invention is directed to this and other unmet needs.SUMMARY OF THE INVENTION
[0006] In one aspect, the present disclosure provides synthetic peptides that are capable of binding to human TLR4. These peptides have an amino acid sequence that is at least 90% identical to any one of the sequences set forth in SEQ ID NOs: 1-9. Some of the peptides have an amino acid sequence that is a conservatively modified variant of any one of the sequences set forth in SEQ ID NOs: 1-9. Some of the peptides have an amino acid sequence that is at least 93% or at least 96% identical to any one of the sequences set forth in SEQ ID NOs: 1-9. Some of the peptides have an amino acid sequence that is identical to any one of the sequences set forth in SEQ ID NOs: 1-9. Preferably, the TLR4-binding peptides of the invention can inhibit TLR4 signaling. In some of these embodiments, the synthetic peptide has an amino acid sequence as set forth in SEQ ID NO: 1 or 2, or a conservatively modified or substantially identical variant sequence thereof. In some of these embodiments, the synthetic peptide has an amino acid sequence as set forth in SEQ ID NO: 1 except for substitutions at one or two residues, e.g., any one of SEQ ID NOs: 11-21.
[0007] In a related aspect, the invention provides polynucleotide molecules that encode the TLR4-binding peptide described herein. Some of the polynucleotides are DNA or mRNA molecules. Also provided in the disclosure are vectors that harbor one or more of the polynucleotide molecules. Some of these vectors are AAV vectors.
[0008] In another related aspect, the disclosure provides compounds that contain a TLR4-binding peptide that is conjugated to a carrier moiety. The TLR4-binding peptide in these compounds has an amino acid sequence that is at least 90% identical to any one of the sequences set forth in SEQ ID NOs: 1-9. In some embodiments, the employed carrier moiety in the conjugate compounds is a carrier protein, an immunoglobulin, a Fc domain, a liposome, or a PEG molecule. In some embodiments, the TLR4-binding peptide present in the conjugate compounds has an amino acid sequence set forth inSEQ ID NO: 1 or 2, or a conservatively modified or substantially identical variant thereof (e.g., SEQ ID NOs: 11-21).
[0009] In another related aspect, the disclosure provides compounds that contain dimerized or multimerized TLR4-binding peptides. Each of the TLR4-binding peptides in these compounds has an amino acid sequence that is at least 90% identical to any one of the sequences set forth in SEQ ID NOs: 1-9. In some of the compounds, the TLR4-binding peptides are attached by linker moieties. In some embodiments, the TLR4-binding peptides each has an amino acid sequence set forth in SEQ ID NO: 1 or 2, or a conservatively modified or substantially identical variant thereof. In some of these compounds, the TLR4-binding peptides each have an amino acid sequence as shown in SEQ ID NO: 1 or a conservatively modified or substantially identical variant thereof (e.g., SEQ ID NOs: 11-21).
[0010] In another aspect, the disclosure provides methods for inhibiting or suppressing Toll-like receptor 4 (TLR4) signaling activities in a subject. The methods entail administering to a subject suffering from undesired TLR4 signaling activities a pharmaceutical composition that contains a therapeutically effective amount of a synthetic TLR4 antagonist peptide, thereby inhibiting or suppressing signaling activities of a Toll-like receptor 4 (TLR4) in the subject. In these methods, the employed synthetic TLR4 antagonist peptide has an amino acid sequence set forth in SEQ ID NO: 1 or 2, or a conservatively modified variant thereof. Some of these embodiments are directed to human subjects that suffer from sepsis, a chronic inflammatory disorder, an ischemia-reperfusion injury, or a myocardial injury. In some methods, the employed TLR4 antagonist peptide has an amino acid sequence as set forth in SEQ ID NO:1. In some methods, the TLR4 antagonist peptide is multimerized or is conjugated to a carrier moiety. In some of these embodiments, the carrier moiety is a carrier protein, an immunoglobulin, a Fc domain, a PEG molecule, or a liposome.
[0011] A further understanding of the nature and advantages of the present invention may be realized by reference to the remaining portions of the specification and claims.BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1. Sequence specific protein-protein interactions in cell membranes between de novo designs and the TLR4 TM domain. A) TMJM fused to smBitcomponent of NanoLuc enzyme was used as the target with de novo designed peptides fused to the IgBit component of NanoLuc to evaluate the interaction capacity with NanoBit in mammalian cell membranes. Expression and trafficking to plasma membrane was confirmed with Flag-immunostaining and widefield microscopy in 293T cells. B) NanoBit luminescence was normalized by HiBit luminescence to quantify protein-protein interaction in cell membranes and revealed all 9 de novo designs formed significantly more interaction with TMJM target than the non-specific control CD8alpha. Design 1 and 6 had significantly higher luminescence than the TMJM self-interacting positive control, qualifying these proteins as lead candidates. C) Majority of de novo designs expressed and trafficked to plasma membrane in a predominantly type I orientation when analyzed with Flag-immunostaining and widefield microscopy in 293T cells.
[0013] Figure 2. Sequence and target specificity of lead anti-TLR4 peptide de novo designs. A) Design model of anti-TLR4 peptide Design 1 and TLR4 TM domain, with interfacial side chains shown highlighting a side chain packing of apolar residues is driving feature establishing helix interface packing. B) Design 1 and Design 6 target were designed using different input backbone geometries to target distinct surfaces on the native TM helix. C) Design model of anti-TLR4 Design 6 and TLR4 TM domain, with interfacial side chains shown highlighting an interchain hydrogen bond and optimized knobs into hole interactions with apolar residues. D) The scrambled version of sequences for Design 1 and 6 had significantly lower normalized luminescence compared to corresponding original design binder in NanoBit, suggesting specific protein-protein interaction is encoded in the primary sequence of each lead design. E) The designs were assayed with NanoBit to determine specificity against a panel of endogenous single and multi-pass membrane protein receptors. Values are reported as fold-change over non-specific control CD8alpha, where a value >1 indicates specific interaction and <1 indicates non-specific interactions with the target receptors.
[0014] Figure 3. Anti-TLR4 peptide Design 6 specifically inhibits LPS induced NFkB signaling. A) Proposed model of inhibition where native TM interactions are required to transmit signal from outside to inside via an active receptor complex. An anti-TLR4 (TLR4 TM targeting) peptide will disrupt active receptor complex signaling via steric disruption of the crucial TM-TM interactions within the lipid bilayer. B) LPS dose curve for TLR4 co-transfected with Design 6 shows lower overall activitycompared to TLR4 co-transfected with an empty vehicle, consistent with a noncompetitive inhibitor. C) Plasmid DNA of an empty vehicle, lead designs, or scrambled versions of lead designs was delivered to an NFkB reporter cells co-transfected with TLR4. When treated with 10 ug / mL LPS and analyzed for activation, Design 6 inhibited specifically compared to its scrambled version while Design 1 and Design 1 scrambled both inhibited moderate levels suggesting an off-target effect (n=3).
[0015] Figure 4. Design 6 induces a dose dependent inhibition for LPS activation in TLR4. A) NFkB response to 10 ug / mL LPS decreases with increasing amounts of Design6 co-transfected in HekBlue cells with TLR4. B) The amount of Design6, quantified by HiBit luminescence increases as the DNA ratio increases relative to pcDNA in TLR4 co-transfections in 293T cells. C) The difference in receptor expression was monitored by TLR4-GFP fluorescence and deemed not significant (ANOVA, p=>0.5) eliminating degradation of TLR4 is the primary mechanism of inhibition for lead designs. D) Relative to TLR4 with no Design6 challenge, the percent of % inhibition increases as amount of Design 6 challenge protein increases, following a sigmoidal trend akin to dose-dependent responses.DETAILED DESCRIPTION OF THE INVENTIONI. Overview
[0016] The present disclosure is predicated in part on studies undertaken by the inventors to identify the TLR4 structure-function relationships hidden within the cell membrane, and to engineer molecular tools to precisely manipulate these mechanisms for tuning or suppressing TLR4 signaling. TLR4 is a type I transmembrane protein with an extracellular domain composed of 22 leucine-rich repeats (LRRs), which mediate LPS recognition and receptor dimerization; a transmembrane domain; and the Toll / IL-1 receptor domain (TIR domain) that is essential for downstream signal transduction. The TLR4 protein is known to homo-dimerize and undergoes conformational changes upon agonist ligand binding, which provides a cross-membrane trigger through its transmembrane spanning domain (TM domain) to initiate downstream signaling cascades leading to inflammatory signaling. Nevertheless, the physiological relevance of TLR4 TM-TM interactions in mammalian cells or in vivo remains unexplored and unvalidated within the context of the full-length receptor.
[0017] As detailed herein, the inventors hypothesized that the largely apolar TM domain of TLR4 inherently encodes molecular recognition and can be synthetically optimized to regulate signal transmission across the lipid bilayer. Using cell-based biochemical assays, the inventors identified that TLR4 molecular interactions within the lipid bilayer are both physiologically relevant and necessary for receptor activation. The inventors also developed a versatile and robust in silico protein design method to generate de novo membrane-targeting molecules. With this advancement, the inventors isolated sequence specific TLR4 TM adaptor molecules and proactively tested their ability to inhibit receptor activity. The TLR4-targeting peptide or polypeptide molecules engineered by computational design were able to inhibit TLR4 function upon LPS challenge, forming stable interactions with the TLR4 TM domain both in cells and in vitro. The molecules exhibited sequence-specific, dose-dependent behavior and demonstrated limited off-target interactions. This represents a significant advancement in membrane protein design and the understanding of TLR4 signaling mechanisms. The results obtained from these studies provide insights into a more integrated cross-membrane signaling mechanism for full-length receptors and offer a framework for future therapeutic strategies that involve receptor TM dimerization in their mechanisms of action.
[0018] The computationally designed synthetic peptides were based on a de novo ~30 amino acid stretch of TM span as the principal binding region for targeting TLR4. As a specific exemplification, one designed peptide molecule (EAPLILWLLLGITAFLILLLIGICLLIMKKL; SEQ ID NO:1), also termed “Design 6” herein, was found to be an active NFkB inhibitor. Specifically, plasmid DNA delivery of Design 6 by transient transfection demonstrated an approximate 50% reduction of TLR4-based NFkB activity with a colorimetric assay in an NFkB-SEAP reporter cell line. Design 6 inhibition is sequence specific, dose dependent, and does not significantly decrease total TLR4 protein levels. The inventors verified that this synthetic peptide forms a stable binding complex with the TLR4 membrane spanning region in cells by split enzyme complementation (NanoBit protein-protein interaction assay) and co-immunoprecipitation. It was observed that the computationally designed TLR4-binding peptide (e.g., Design 6) bind to TLR4 and forms an inhibitory regulatory complex. It was further found that this core binding sequence is very hydrophobic, which can be delivered by genetic format such as mRNA or an expression vector (e.g.,AAV). Taken together, results from these studies indicate that the synthetic peptide molecules described herein have the potential as TLR4 antagonists that can be used to regulate TLR4 in a multitude of inflammatory pathologies by mitigating hyperactive TLR4 signaling.
[0019] In accordance with these studies, the present disclosure provides novel compositions for inhibiting undesired or aberrant TLR4 signaling activities and for treating diseases and disorders induced by or associated with TLR4 signaling activities. Examples of such diseases include sepsis, inflammatory or autoimmune disorders such as atherosclerosis and lupus, and ischemia-reperfusion injuries and myocardial dysfunctions. Subjects suitable for treatment with methods of the invention include ones who have or are at risk of developing any of these diseases.
[0020] There are a number of advantages associated with the inventions described herein.There are currently no FDA approved TLR4 antagonists. Existing chemical probes or potential leads for targeting TLR4 are chemical derivatives of lipidic endotoxins or small molecules obtained from high throughput screening, which often target reactive cysteines with questionable specificity. For example, Eritoran, a synthetic TLR4-targeting lipid, failed development at a 5-year phase 3 clinical trial with indication for treatment of human sepsis due to lack of efficacy. Known peptide-based TLR4 ligands that have been engineered to date only have unsatisfactory binding affinities (e.g., a KD of around 20 pM). Likewise, while there are antibodies or other soluble molecules that can modulate TLR4, it is well established that the TLR4 protein initiate signaling cascades both at the cell surface and within endosomes upon internalization. In contrast, the engineered synthetic transmembrane proteins described herein represent a unique class of molecular agents which can target TLR4 within all cellular membrane compartments, not just surface localized TLR4. Further, this novel molecular class of membrane-soluble / spanning polypeptides are not limited by covalent cysteine promiscuity, and do not have an endotoxin lipid chemical backbone. By standard gene therapy approaches, these agents can be consistently delivered to desired tissues area, providing sustained regulation of autoinflammation. Moreover, the TLR4 targeting synthetic peptides can be provided in peptide-based formulations for administration via, e.g., injection, topical administration, or as lipid nanoparticles.
[0021] Unless otherwise stated, the present invention can be performed using standard procedures, as described, for example in Methods in Enzymology, Volume 289: Solid-Phase Peptide Synthesis, J. N. Abelson, M. I. Simon, G. B. Fields (Editors), Academic Press; 1st edition (1997) (ISBN-13: 978-0121821906); U.S. Pat. Nos.4,965,343, and 5,849,954; Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., USA (1982);Sambrook et al., Molecular Cloning: A Laboratory Manual (2nd ed.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., USA (1989); Davis et al., Basic Methods in Molecular Biology, Elsevier Science Publishing, Inc., New York, USA (1986); or Methods in Enzymology: Guide to Molecular Cloning Techniques Vol. 152, S. L. Berger and A. R. Kimmerl Eds., Academic Press Inc., San Diego, USA (1987); Current Protocols in Protein Science (CPPS) (John E. Coligan, et. al., ed., John Wiley and Sons, Inc.), Current Protocols in Cell Biology (CPCB) (Juan S. Bonifacino et. al. ed., John Wiley and Sons, Inc.), and Culture of Animal Cells: A Manual of Basic Technique by R. Ian Freshney, Publisher: Wiley-Liss; 5th edition (2005), Animal Cell Culture Methods (Methods in Cell Biology, Vol. 57, Jennie P. Mather and David Barnes editors, Academic Press, 1st edition, 1998). The following sections provide additional guidance for practicing the compositions and methods of the present invention.
[0022] The following sections provide more detailed guidance for practicing the invention.II. Definitions
[0023] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which this invention pertains. The following references provide one of skill with a general definition of many of the terms used in this invention: Academic Press Dictionary of Science and Technology, Morris (Ed.), Academic Press (1sted., 1992); Oxford Dictionary of Biochemistry and Molecular Biology , Smith et al. (Eds.), Oxford University Press (revised ed., 2000); Encyclopaedic Dictionary of Chemistry, Kumar (Ed.), Anmol Publications Pvt. Ltd. (2002); Dictionary of Microbiology and Molecular Biology, Singleton et al. (Eds.), John Wiley & Sons (3rded., 2002); Dictionary of Chemistry, Hunt (Ed.), Routledge (1sted., 1999); Dictionary of PharmaceuticalMedicine, Nahler (Ed.), Springer-Verlag Telos (1994); Dictionary of Organic Chemistry, Kumar and Anandand (Eds.), Anmol Publications Pvt. Ltd. (2002); and A Dictionary of Biology (Oxford Paperback Reference) , Martin and Hine (Eds.), Oxford University Press (4thed., 2000). In addition, the following definitions are provided to assist the reader in the practice of the invention.
[0024] The singular terms "a," "an," and "the" include plural referents unless the context clearly indicates otherwise. Similarly, the word "or" is intended to include "and" unless the context clearly indicates otherwise.
[0025] The term "agent" includes any substance, molecule, element, compound, entity, or a combination thereof. It includes, but is not limited to, e.g., protein, polypeptide, small organic molecule, polysaccharide, polynucleotide, and the like. It can be a natural product, a synthetic compound, or a chemical compound, or a combination of two or more substances. Unless otherwise specified, the terms “agent”, “substance”, and “compound” are used interchangeably herein.
[0026] The term "analog" or “derivative” is used herein to refer to a molecule that structurally resembles a reference molecule but which has been modified in a targeted and controlled manner, by replacing a specific substituent of the reference molecule with an alternate substituent. Compared to the reference molecule, an analog would be expected, by one skilled in the art, to exhibit the same, similar, or improved utility. Synthesis and screening of analogs to identify variants of known compounds having improved traits (such as higher binding affinity for a target molecule) is an approach that is well known in pharmaceutical chemistry.
[0027] As used herein, the term "amino acid" of a peptide refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, y-carboxy glutamate, and O-phosphoserine. Amino acid analogs refer to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. The synthetic TLR4targeting peptides of the invention encompass derivatives or analogs which have been modified with non-naturally coding amino acids.
[0028] As used herein the term "comprising" or "comprises" is used in reference to compositions, methods, and respective component(s) thereof, that are essential to the invention, yet open to the inclusion of unspecified elements, whether essential or not.
[0029] As used herein the term "consisting essentially of refers to those elements required for a given embodiment. The term permits the presence of elements that do not materially affect the basic and novel or functional characteristic(s) of that embodiment of the invention.
[0030] The term "consisting of refers to compositions, methods, and respective components thereof as described herein, which are exclusive of any element not recited in that description of the embodiment.
[0031] The term "conservatively modified variant" or “conservatively substituted variant” applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refer to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are “silent variations,” which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid that encodes a polypeptide is implicit in each described sequence.
[0032] For polypeptide or peptide sequences, “conservatively modified variants” refer to a variant which has conservative amino acid substitutions, amino acid residues replaced with other amino acid residue having a side chain with a similar charge.Families of amino acid residues having side chains with similar charges have beendefined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).
[0033] Administration "in conjunction with" one or more other therapeutic agents includes simultaneous (concurrent) and consecutive administration in any order.
[0034] As used herein, a “derivative” of a reference molecule (e.g., a TLR4-targeting peptide disclosed herein) is a molecule that is chemically modified relative to the reference molecule while substantially retaining the biological activity. The modification can be, e.g., oligomerization or polymerization, modifications of amino acid residues or peptide backbone, cross-linking, cyclization, conjugation, fusion to additional heterologous amino acid sequences, or other modifications that substantially alter the stability, solubility, or other properties of the peptide. In some embodiments, derivatives of the exemplified TLR4-binding peptides (e.g., conservatively modified variants of Design 6) have improved water solubility relative to the original peptide.
[0035] Inflammation" or "inflammatory response" refers to an innate immune response that occurs when tissues are injured by bacteria, trauma, toxins, heat, or any other cause. The damaged tissue releases compounds including histamine, bradykinin, and serotonin. Inflammation refers to both acute responses (i.e., responses in which the inflammatory processes are active) and chronic responses (i.e., responses marked by slow progression and formation of new connective tissue). Acute and chronic inflammation can be distinguished by the cell types involved. Acute inflammation often involves polymorphonuclear neutrophils; whereas chronic inflammation is normally characterized by a lymphohistiocytic and / or granulomatous response.Inflammation includes reactions of both the specific and non-specific defense systems. A specific defense system reaction is a specific immune system reaction response to an antigen (possibly including an autoantigen). A non-specific defense system reaction is an inflammatory response mediated by leukocytes incapable of immunological memory. Such cells include granulocytes, macrophages, neutrophils and eosinophils.
[0036] Signaling activities of Toll-like receptor 4 (TLR4) or TLR4-mediated signaling pathways refer to biological activities and cellular responses induced by the interaction of TLR4 with its cognate ligands (e.g., microbial molecules such as LPS), and biochemical reactions associated with the cascade of signaling events initiated by the receptor / ligand interaction. These activities encompass interaction of TLR4 with their adaptors, e.g., binding to MyD88 via its cytoplasmic Toll / interleukin-1 receptor (TIR) domains. TLR4 signaling activities also include activities associated with recruitment of downstream mediators, innate immune response thereafter induced which provides immediate host protection, and stimulation of the host’s adaptive immune response (e.g., via activation and maturation of APCs together with production of inflammatory cytokines). For example, TLR4 signaling activities encompass activation of NFKB and stimulation of costimulatory molecule (CD 14) expression in macrophages.
[0037] TLR4 mediated immune responses refer to immune responses elicited in a host via recognition by TLR4 of pathogen-associated molecular patterns as well as various endogenous ligands. In addition to innate immunity induced by TLR4 recognition of a cognate ligand (e.g., LPS), TLR4 mediated immune responses also refer to stimulation of adaptive immune reactions as a result of TLR4-mediated signaling activities (e.g., cytokine productions and antigen presentation).
[0038] The term "subject" for purposes of treatment refers to any animal classified as a mammal, e.g., human and non-human mammals. Examples of non-human animals include dogs, cats, cattle, horses, sheep, pigs, goats, rabbits, and etc. Unless otherwise noted, the terms “patient” or “subject” are used herein interchangeably. Preferably, the subject is human.
[0039] The terms "decrease" , "reduced", "reduction" , "decrease" and "inhibit" are all used herein generally to mean a decrease by a statistically significant amount. However, for avoidance of doubt, ""reduced", "reduction" or "decrease" or "inhibit" means a decrease by at least 10% as compared to a reference level, for example a decrease by at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% or up to and including a 100% decrease (e.g. absent level as compared to a reference sample), or any decrease between 10-100% as compared to a reference level.
[0040] The term “treating” or “alleviating” includes the administration of compounds or agents to a subject to prevent or delay the onset of the symptoms, complications, or biochemical indicia of a disease (e.g., a disorder mediated by or associated with aberrant TLR4 signaling activities), alleviating the symptoms or arresting or inhibiting further development of the disease, condition, or disorder.Subjects in need of treatment include those already suffering from the disease or disorder as well as those being at risk of developing the disorder. Treatment may be prophylactic (to prevent or delay the onset of the disease, or to prevent the manifestation of clinical or subclinical symptoms thereof) or therapeutic suppression or alleviation of symptoms after the manifestation of the disease. In the treatment of a disease or disorder associated with or mediated by TLR4 signaling, a therapeutic agent may directly decrease the pathology of the disease, or render the disease more susceptible to treatment by other therapeutic agents.III. Synthetic TLR4-binding peptides and derivative TLR4 antagonist compounds
[0041] The invention provides compositions and therapeutic methods related to synthetic TLR4-targeting molecules or compounds. The TLR4-targeting molecules contain a synthetic TLR4-binding peptide that is obtained by computational design as described herein. Exemplary TLR4-binding peptides of the invention are shown in SEQ ID NOs:l-9. TLR4-binding peptides of the invention also encompass peptides that have an amino acid sequence that is substantially identical to one of these exemplified peptide sequences. In various embodiments, the TLR4-binding peptide can have an amino acid sequence that is at least 90%, 92%, 93%, 95%, 96% or 97% identical to one of the exemplified peptide sequences (e.g., SEQ ID NO:1). In some of these embodiments, the TLR4-binding peptide has an amino acid sequence that is a conservatively modified variant of the exemplified peptide sequence. In addition to these TLR4-binding peptides, the synthetic TLR4-targeting molecules or compounds of the invention also encompass derivatives or variants that are derived from the TLR4-binding peptides. As detailed below, these include peptide variants with natural or nonnatural amino acid substitutions, peptidomimetics derived from the TLR4-binding peptides, multimers of the TLR4-binding peptides, and other conjugates or fusion molecules containing the TLR4-binding peptides. In some embodiments, the peptide variants has an amino acid sequence as set forth in SEQ ID NO: 1 except forsubstitutions at one or two residues. Examples of such variant peptides include, e.g., EAPLFLWLLLGITAFLILLLIGICLLIMKKL (SEQ ID NO: 11), EAPLILWLALGITAFLILLLIGICLLIMKKL (SEQ ID NO: 12), EAPLILWLLLGIFAFLILLLIGICLLIMKKL (SEQ ID NO: 13), EAPLILWLLLGITLFLILLLIGICLLIMKKL (SEQ ID NO: 14), EAPLILWLLLGITAFLALLLIGICLLIMKKL (SEQ ID NO: 15), EAPLILWLLLGITAFLIALLIGICLLIMKKL (SEQ ID NO: 16), EAPLILWLLLGITAFLILALIGICLLIMKKL (SEQ ID NO: 17), EAPLILWLLLGITAFLILLIIGICLLIMKKL (SEQ ID NO: 18), EAPLILWLLLGITAFLILLAIGICLLIMKKL (SEQ ID NO: 19), EAPLILWLLLGITAFLILLLIGICLLLMKKL (SEQ ID NO:20), and EAPLILWLLLGITAFLILLLIGICLLAMKKL (SEQ ID NO:21).
[0042] In addition to a TLR4-binding peptide as shown in SEQ ID NOs: 1-9 (or a variant noted above), the TLR4-binding peptides or derivative TLR4 antagonist compounds of the invention can contain other structural components (e.g., linker motifs) as included in the protein constructs exemplified herein. For example, they can have an N-terminal signal peptide to facilitate protein trafficking to the plasma membrane. Suitable N-terminal signal peptides include influenza signal sequence ssHA as exemplified herein. Other well-known protein signal peptides routinely used by the skilled artisans, e.g., human tissue plasminogen activator (tPA) signal sequence and interleukin-6 (IL-6) signal sequence, can also be readily employed in the practice of the present invention.
[0043] Preferably, the synthetic TLR4-targeting molecules of the invention, including the TLR4-binding peptides from which they are derived, are antagonists of the TLR4 signaling pathway. Such agents can be useful for suppressing inflammation and treating inflammatory conditions or disorders that are associated with or mediated by aberrant TLR4 signaling. In general, they are capable of antagonizing one or more TLR4 signaling activities. TLR4-antagonizing activities of these agents encompass any activity in suppressing or inhibiting one or more biological activities or cellular responses that are mediated or induced by the TLR4 signaling pathway. These include, e.g., inhibition of TLR4 binding to MyD88, inhibition of recruitment of mediators or other molecules required for TLR4 signaling, suppression of the activation of downstream signaling pathways (e.g., NFKB pathway), and downregulation ofinflammatory cytokines. Any of these activities can be readily assessed with methods that are well known in the art. For example, activities of the TLR4-taregeting synthetic peptides in inhibiting NFKB pathway can be monitored by using a NFKB reporter cell. Typically, the reporter cell (e.g., a HEK293T cell) contains a construct that expresses a reporter molecule (e.g., alkaline phosphatase) under the control of NF-KB response elements. Upon stimulation of TLR4 signaling by LPS, inhibitory activities of the peptides on the downstream NFKB pathway can be readily determined by monitoring expression of the reporter molecule from the reporter cell, as exemplified herein (see, e.g., Example 5). Specific examples of TLR4 antagonists of the invention include the TLR4-binding antagonist peptide as set forth in SEQ ID NO: 1 (“Design 6”) or SEQ ID NO:2 (“Design 1”), as well as derivative or variants compounds of these TLR4-binding peptides.
[0044] In addition to the peptides noted above, TLR4-targeting antagonist molecules of the invention also include related or derivative compounds that are derived from one of the exemplified peptides (e.g.., SEQ ID NO:1). These related or derivative compounds encompass variants, analogs, mimetics, complexes or fusion molecules containing the peptides, and other compounds derived from the TLR4-targeting antagonist peptides. In some preferred embodiments, the derivative compounds possess substantially the same chemical or biological activities as the TLR4-targeting antagonist peptides or polypeptides exemplified herein (e.g., SEQ ID NO:1). As noted above, the related or derivative compounds can include, e.g., peptides or polypeptides that have substantially identical sequences, e.g., conservatively modified variants. Related or derivative TLR4 antagonist compounds suitable for the invention also encompass variants, analogs, multimers, peptidomimetics, fusions with other molecules (e.g., carrier moieties) or other derivatives that can be generated from the TLR4-targeting antagonist peptides exemplified herein (e.g., SEQ ID NO:1). These derivative compounds can be subject to the appropriate assays or screening methods to identify TLR4 antagonists with optimized activities. In some embodiments, the derivative compounds are modified versions of the exemplified peptides which are generated by conservative amino acid substitutions. In some other embodiments, the derivative compounds are variants produced by non-conservative substitutions to the extent that that they substantially retain the activities of those peptides. Modification to a TLR4-targeting antagonist peptide can be performed with standard techniquesroutinely practiced in the art (e.g., U.S. Patent Applications 20080090760 and 20060286636).
[0045] In some embodiments, the derivative compounds of an exemplified TLR4-targeting antagonist polypeptide of the invention (e.g., peptide containing SEQ ID NO: 1) are analogs or that contain one or more naturally occurring amino acid derivatives of the twenty standard amino acids, for example, 4-hydroxyproline, 5-hydroxylysine, 3-methylhistidine, homoserine, ornithine or carb oxy glutamate, and can include amino acids that are not linked by polypeptide bonds. Similarly, they can also be cyclic polypeptides and other conformationally constrained structures. Methods for modifying a polypeptide to generate analogs and derivatives are well known in the art, e.g., Roberts and Vellaccio, The Peptides: Analysis, Synthesis, Biology, Eds. Gross and Meinhofer, Vol. 5, p. 341, Academic Press, Inc., New York, N.Y. (1983); and Burger ’s Medicinal Chemistry and Drug Discovery, Ed. Manfred E. Wolff, Ch. 15, pp. 619-620, John Wiley & Sons Inc., New York, N.Y. (1995).
[0046] Some other derivative compounds of the exemplified TLR4-targeting antagonist polypeptides are peptidomimetics. Peptidomimetics based on a TLR4-targeting antagonist peptide (e.g., SEQ ID NO:1) substantially retain the activities of the reference peptide. They include chemically modified peptides or polypeptides, polypeptide-like molecules containing non-naturally occurring amino acids, peptoids and the like, that have a structure substantially the same as the reference polypeptide or peptide upon which the peptidomimetic is derived (see, for example, Burger's Medicinal Chemistry and Drug Discovery, 1995, supra). For example, the peptidomimetics can have one or more residues chemically derivatized by reaction of a functional side group. In addition to side group derivatizations, a chemical derivative can have one or more backbone modifications including alpha-amino substitutions such as N-methyl, N-ethyl, N-propyl and the like, and alpha-carbonyl substitutions such as thioester, thioamide, guanidino and the like. Typically, a peptidomimetic shows a considerable degree of structural identity when compared to the reference polypeptide and exhibits characteristics which are recognizable or known as being derived from or related to the reference polypeptide. Peptidomimetics include, for example, organic structures which exhibit similar properties such as charge and charge spacing characteristics of the reference polypeptide. Peptidomimetics also can includeconstrained structures so as to maintain optimal spacing and charge interactions of the amino acid functional groups.
[0047] In some embodiments, derivative compounds of TLR4-targeting antagonist peptides or polypeptides described herein are molecules that have the peptides or polypeptides covalently or non-covalently conjugated to a carrier moiety via any conventional methods. A “carrier moiety” (“carrier” or “carrier molecule”) is a conjugation partner capable of enhancing the immunogenicity of a polypeptide.Suitable carriers are typically large, slowly metabolized macromolecules such as proteins; polysaccharides (such as latex functionalized SEPHAROSE™, agarose, cellulose, cellulose beads and the like); polymeric amino acids (such as polyglutamic acid, polylysine, and the like); amino acid copolymers; and inactive virus particles or attenuated bacteria, such as Salmonella. In various embodiments, the carrier moiety can be a carrier protein, an immunoglobulin, a Fc domain, a PEG molecule or other polymer. In some embodiments, the carrier protein is an integral membrane protein from, e.g., E. coli and other bacteria are useful conjugation partners. Examples include serum albumins, keyhole limpet hemocyanin (KLH), certain immunoglobulin molecules, thyroglobulin, ovalbumin, bovine serum albumin (BSA), tetanus toxoid (TT), and diphtheria toxoid (CRM). In still some other embodiments, the carrier moiety can be a polymer other than a protein or polypeptide. Examples of such polymers include, e.g., carbohydrates such as dextran, mannose or mannan. In some other embodiments, the employed carrier moiety can be a liposome. Loading a TLR4-binding peptide or variant of the invention (e.g., Design 6) onto a liposome for therapeutic applications can be readily performed by following standard protocols that are well known in the art. See, e.g., Sonju et al., J. Control. Release. 2020; 329: 624-644; Cui et al., Pharmaceuticals (Basel). 2022; 15:1072; and Jash et al., J. Mater. Chem. B. 2021; 9:4773-4792.
[0048] In some embodiments, the TLR4-targeting antagonist peptides, variants or derivatives described herein are dimerized or multimerized molecules. In some of these embodiments, dimerization or multimerization of the TLR4-targeting antagonist agents can be achieved by covalent attachment to at least one linker moiety. Either homologous multimerization or heterologous multimerization of TLR4-targeting antagonist peptides can be achieved via various suitable means. For example, the peptides can be covalently linked via recombinant techniques. In some embodiments,the multimerized molecules of the invention can utilize a carrier moiety noted above. In some of these embodiments, a carrier molecule or moiety can be used to conjugate two TLR4-targeting antagonist peptides. The two TLR4-targeting antagonist peptides can be identical (e.g., SEQ ID NO:1) or different (e.g., SEQ ID NO:1 and SEQ ID NO:2).
[0049] The TLR4-targeting antagonist peptides described herein can be joined by other chemical bond linkages, such as linkages by disulfide bonds or by chemical bridges. In some other embodiments, the TLR4-targeting antagonist peptides described herein can be linked physically in tandem to form a polymer of TLR4-targeting antagonist peptides. The peptides making up such a polymer can be spaced apart from each other by a peptide linker, e.g., a glycine linker. In various embodiments, the glycine linker can contain from about 2 to about 20 glycine residues. In some embodiments, other molecular biology techniques well known in the art can be used to create a polymer of peptides. In some embodiments, polyethylene glycol (PEG) may serve as a linker that dimerizes two peptide monomers. For example, a single PEG moiety containing two reactive functional groups may be simultaneously attached to the N-termini of both peptide chains of a peptide dimer. These peptides are referred to herein as “PEGylated peptides.” In some embodiments, the peptide monomers of the invention may be oligomerized using the biotin / streptavidin system.
[0050] Methods for stabilizing peptides known in the art may be used with the methods and compositions described herein. For example, using D-amino acids, using reduced amide bonds for the peptide backbone, and using non-peptide bonds to link the side chains, including, but not limited to, pyrrolinone and sugar mimetics can each provide stabilization. The design and synthesis of sugar scaffold peptide mimetics are described in the art, e.g., Hirschmann et al., J. Med. Chem. 36, 2441-2448, 1996.Further, pyrrolinone-based peptide mimetics present the peptide pharmacophore on a stable background that has improved bioavailability characteristics. See, e.g., Smith et al., J. Am. Chem. Soc. 122, 11037-11038, 2000.
[0051] In some embodiment, derivative compounds of the exemplified TLR4-targeting antagonist peptides or polypeptides include modifications within the sequence, such as, modification by terminal -NH2 acylation, e.g., acetylation, or thiogly colic acid amidation, by terminal-carboxylamidation, e.g., with ammonia, methylamine, and the like terminal modifications. One can also modify the amino and / or carboxy termini of the polypeptides described herein. Terminal modificationsare useful to reduce susceptibility by proteinase digestion, and therefore can serve to prolong half-life of the polypeptides in solution, particularly in biological fluids where proteases may be present. Amino terminus modifications include methylation (e.g., -NHCH3 or -N(CH3)2), acetylation (e.g., with acetic acid or a halogenated derivative thereof such as a-chloroacetic acid, a-bromoacetic acid, or a-iodoacetic acid), adding a benzyloxycarbonyl (Cbz) group, or blocking the amino terminus with any blocking group containing a carboxylate functionality defined by RCOO- or sulfonyl functionality defined by R-SO2-, where R is selected from the group consisting of alkyl, aryl, heteroaryl, alkyl aryl, and the like, and similar groups. One can also incorporate a desamino acid at the N-terminus (so that there is no N-terminal amino group) to decrease susceptibility to proteases or to restrict the conformation of the peptide compound. In some embodiments, the N-terminus is acetylated with acetic acid or acetic anhydride.
[0052] Carboxy terminus modifications include replacing the free acid with a carboxamide group or forming a cyclic lactam at the carboxy terminus to introduce structural constraints. One can also cyclize the peptides described herein (e.g., SEQ ID NO: 1), or incorporate a desamino or descarboxy residue at the termini of the peptide, so that there is no terminal amino or carboxyl group, to decrease susceptibility to proteases or to restrict the conformation of the peptide. Methods of circular peptide synthesis are known in the art, for example, in U.S. Patent Application No. 20090035814; and Muralidharan and Muir, Nat. Methods, 3:429-38, 2006. C-terminal functional groups of the peptides described herein include amide, amide lower alkyl, amide di(lower alkyl), lower alkoxy, hydroxy, and carboxy, and the lower ester derivatives thereof, and the pharmaceutically acceptable salts thereof.
[0053] The TLR4-targeting antagonist peptide or polypeptide compounds described herein also serve as structural models for non-peptidic compounds with similar biological activity. There are a variety of techniques available for constructing compounds with the same or similar desired biological activity as the exemplified TLR4-targeting antagonist peptides, but with more favorable activity with respect to solubility, stability, and susceptibility to hydrolysis and proteolysis. See, e.g., Morgan and Gainor, Ann. Rep. Med. Chem. 24:243-252, 1989. These techniques include, but are not limited to, replacing the peptide backbone with a backbone composed ofphosphonates, amidates, carbamates, sulfonamides, secondary amines, and N-methylamino acids.IV. Synthesis of TLR4-targeting antagonist peptides and related compounds
[0054] The TLR4-targeting antagonist peptides or polypeptides described herein, including variants and derivatives thereof, can be chemically synthesized and purified by standard chemical or biochemical methods that are well known in the art. Some of the methods for generating analog or derivative compounds of the TLR4-targeting antagonist polypeptides are described above. Other methods that may be employed for producing the TLR4-antagonizing polypeptides of the invention and their derivative compounds include, e.g., solid phase peptide synthesis. For example, the peptides can be synthesized using t-Boc (tert-butyl oxy carbonyl) or FMOC (9-flourenylmethloxycarbonyl) protection group described in the art. See, e.g., Merrifield, J. Am. Chem. Soc. 85:2149-2154, 1963; “Peptide synthesis and applications” in Methods in molecular biology Vol. 298, Ed. by John Howl; “Chemistry of Peptide Synthesis” by N. Leo Benoiton, 2005, CRC Press, (ISBN-13: 978-1574444544); and “Chemical Approaches to the Synthesis of Peptides and Proteins” by P. Lloyd-Williams, et. al., 1997, CRC-Press, (ISBN-13: 978-0849391422), Methods in Enzymology, Volume 289: Solid-Phase Peptide Synthesis, J. N. Abelson, M. I. Simon, G. B. Fields (Editors), Academic Press; 1st edition (1997) (ISBN-13: 978-0121821906); U.S. Pat. Nos. 4,965,343, and 5,849,954. In some embodiments, the peptides can be obtained via solid phase synthesis using peptide synthesizing machines. Commercial peptide synthesizing machines are available for solid phase peptide synthesis. For example, the Advanced Chemtech Model 396 Multiple Peptide Synthesizer and an Applied Biosystems Model 432A Peptide synthesizer are suitable. There are commercial companies that make custom synthetic peptides to order, e.g., Abbiotec, Abgent, AnaSpec Global Peptide Services, LLC., Invitrogen, and rPeptide, LLC.
[0055] In some related embodiments, the invention provides polynucleotides (DNA or RNA including mRNA) which encode the TLR4-targeting peptides or polypeptides described herein, including multimers (e.g., dimers) containing more than one of the exemplified peptides. Expression vectors such as adeno-associated virus (AAV) vectors for expressing the polynucleotides, and engineered host cells harboring the vectors, arealso provided in the invention. In some embodiments, the polynucleotide encoding the TLR4-targeting peptide or polypeptide is operationally linked to a promoter in the expression vectors. The expression construct can further comprise a secretory sequence to assist purification of the peptide from the cell culture medium. The host cells to which the vectors are introduced can be any of a variety of expression host cells well known in the art, e.g., bacteria (e.g., E. coli), yeast cell, or mammalian cells. The polynucleotides of the invention and the related vectors and host cells can be used for recombinant production of the encoded TLR4-binding peptides or polypeptides.Recombinant protein expression in different host cells can be constitutive or inducible with inducers such as copper sulfate, or sugars such as galactose, methanol, methylamine, thiamine, tetracycline, or IPTG. After the protein is expressed in the host cells, the host cells are lysed to liberate the expressed protein for purification. A preferred purification method is affinity chromatography such as ion-metal affinity chromatograph using nickel, cobalt, or zinc affinity resins for histidine-tagged peptide. Methods of purifying histidine-tagged recombinant proteins are described by Clontech using their Talon® cobalt resin and by Novagen in their pET system manual, 10th edition. Another preferred purification strategy is by immuno-affinity chromatography, for example, anti-Myc antibody conjugated resin can be used to affinity purify Myc-tagged peptide. Enzymatic digestion with serine proteases such as thrombin and enterokinase cleave and release the peptide from the histidine or Myc tag, releasing the recombinant peptide from the affinity resin while the histidine-tags and Myc-tags are left attached to the affinity resin.
[0056] Cell-free expression systems can also be used for producing TLR4-antagonizing polypeptides of the invention. Cell-free expression systems offer several advantages over traditional cell-based expression methods, including the easy modification of reaction conditions to favor protein folding, decreased sensitivity to product toxicity and suitability for high-throughput strategies such as rapid expression screening or large amount protein production because of reduced reaction volumes and process time. The cell-free expression system can use plasmid or linear DNA.Moreover, improvements in translation efficiency have resulted in yields that exceed a milligram of protein per milliliter of reaction mix. An example of a cell-free translation system capable of producing proteins in high yield is described by Spirin et. al., Science 242: 1162, 1988. The method uses a continuous flow design of the feedingbuffer which contains amino acids, adenosine triphosphate (ATP), and guanosine triphosphate (GTP) throughout the reaction mixture and a continuous removal of the translated polypeptide product. The system uses E. coli lysate to provide the cell-free continuous feeding buffer. This continuous flow system is compatible with both prokaryotic and eukaryotic expression vectors. An example of large scale cell-free protein productions is described in Chang et. al., Science 310:1950-3, 2005. Other commercially available cell-free expression systems include the Expressway™ Cell-Free Expression Systems (Invitrogen) which utilize an E. coli-based in-vitro system for efficient, coupled transcription and translation reactions to produce up to milligram quantities of active recombinant protein in a tube reaction format; the Rapid Translation System (RTS) (Roche Applied Science) which also uses an E. coli-based in-vitro system; and the TNT Coupled Reticulocyte Lysate Systems (Promega) which uses a rabbit reticulocyte-based in-vitro system.V. Therapeutic applications of synthetic TLR4 antagonist peptides
[0057] TLR4 is expressed on a large number of immune cells as well as epithelial cells and plays an essential role in the activation of the innate immune response to microbial pathogens. They impact on adaptive immune reactions and contribute to the initiation and maintenance of the inflammatory response to a multitude of potential microbial pathogens through recognition of pathogen-associated molecular patterns. TLR4 also interacts with a variety of endogenous human ligands and influences the activity of a wide range of tissues and cell processes. Undesired TLR4 signaling activities or TLR4 mediated immune responses are present or implicated in various diseases and disorders, which are also termed herein “diseases or disorders mediated by or associated with aberrant TLR4 signaling”. These diseases include disorders arising from immune response to bacterial or viral infections, allergies, autoimmune disorders, and various inflammatory disorders. TLR4 signaling activities also play a role in increased tumor growth and immunosuppression. Thus, the synthetic TLR4 peptide antagonists of the invention can also be used to prevent inflammation-induced carcinogenesis or cancer progression. Specific examples of conditions or disorders mediated by or associated with aberrant TLR4 signaling include sepsis, allergic asthma, colitis, ischemia-reperfusion injuries, acute respiratory distress syndrome, myocardial injuries (e.g., cardiac ischemia), coronary artery diseases (e.g., atherosclerosis),inflammatory disorders (e.g., asthma, inflammatory bowel disease, rheumatoid arthritis, and skin inflammatory diseases such as psoriasis), systemic autoimmune diseases (e.g., systemic lupus erythematosus (SLE), scleroderma and Sjogren's syndrome), , other undesired inflammation (e.g., neuroinflammation, inflammatory pain, or inflammation associated with injury), ventricular remodeling, vascular collapse, acute tubular necrosis, psoriasis, rheumatoid arthritis, pre-term birth, fertility, cancer angiogenesis and transplant rejection.
[0058] The synthetic TLR4-binding peptides and the derivative TLR4 antagonist compounds disclosed in the invention, as well as polynucleotides (e.g., mRNA or expression vectors) encoding the peptides or derivatives, can be employed to inhibit, suppress or ameliorate undesired TLR4 signaling activities or TLR4 mediated immune responses in subjects suffering from any of the above noted diseases or disorders. As demonstrated in the Examples below, these compounds are capable of inhibiting NFKB activation through TLR4 signaling pathway. Thus, some embodiments of the invention are directed to inhibiting or suppressing undesired or abnormal signaling activities or immune responses mediated by TLR4. In order to better inhibit or suppress an undesired TLR4 signaling activity or TLR4 mediated immune response, these synthetic TLR4 antagonist peptides can be used in conjunction with other known immunosuppressants, e.g., glucocorticoids, azathioprine, cyclosporine, and tacrolimus.
[0059] In some embodiments, the invention provides methods for inhibiting or suppressing undesired TLR4 signaling activities or immune responses in subjects suffering from acute diseases induced or mediated by infections, e.g., sepsis. Sepsis is a medical condition resulting from the immune response to a severe bacterial infection. Septicaemia is sepsis of the bloodstream caused by bacteremia, which is the presence of bacteria in the bloodstream. The term septicaemia is also used to refer to sepsis in general. Symptoms of sepsis are often related to the underlying infectious process. When the infection crosses into sepsis, the resulting symptoms are tachycardia, tachypnea, fever and / or decreased urination. The immunological response that causes sepsis is a systemic inflammatory response causing widespread activation of inflammation and coagulation pathways. This may progress to dysfunction of the circulatory system and, even under optimal treatment, may result in the multiple organ dysfunction syndrome and eventually death.
[0060] The involvement of TLR4 and cytokines in sepsis has been well documented. TLR4 initiates the inflammatory processes that underlie the clinical response to infections in sepsis and septic shock. In Gram negative bacterial infection, activation of blood monocytes and tissue macrophages occurs through LPS mediated TLR4 receptor signaling (Andonegui et al., J Clin. Invest. Ill: 1011-1020, 2003; and Tsujimoto et al., Shock 23:39-44, 2005). It was shown that TLR4 plays a key role for regulating the expression of relevant cytokines within the lung during endotoxic shock (Baumgarten et al., Eur J Anaesthesiol. 23:1041-8, 2006). The TLR4 mediated signaling pathway is known to be critical for the induction of IL-1, IL-8, and IL- 18 that results in the activation of NF-KB and mitogen activated protein (MAP) kinase. Gram positive bacteria may also induce a septic response by a number of cellular components including peptidoglycans, teichoic acids, exotoxins and superantigens. It has been shown that not only is TLR4 a necessary receptor for the innate immune response to LPS, but also critical in the response to staphylococcal enterotoxin B (Calkins et al., J Surg Res 104: 124-130, 2002). Therefore, the synthetic TLR4 antagonist peptides disclosed herein can be employed to inhibit or suppress undesired TLR4 signaling activities in subjects with either Gram negative or Gram-positive sepsis.
[0061] Conventional treatment of sepsis rests on antibiotics, surgical drainage of infected fluid collections, fluid replacement and appropriate support for organ dysfunction. This may include hemodialysis in kidney failure, mechanical ventilation in pulmonary dysfunction, transfusion of blood products, and drug and fluid therapy for circulatory failure. Ensuring adequate nutrition, if necessary by parenteral nutrition, is important during prolonged illness. The synthetic TLR4 antagonist peptides and related compounds disclosed herein can be used alone to treat subjects who have been diagnosed to have sepsis as well as subjects who are at the risk of developing sepsis. Alternatively, these therapeutic agents can be employed in conjunction with a conventional treatment regimen, e.g., antibiotics.
[0062] In some other embodiments, the invention provides methods for inhibiting or suppressing undesired TLR4 signaling activities or immune responses that are associated with chronic disorders in which TLR4 signaling play a role. Examples of such chronic disorders include chronic inflammatory disorders such as atherosclerosis and autoimmune diseases such as lupus. For example, atherosclerosis is a chronic inflammatory disorder affecting the arterial blood vessel. It is a chronic inflammatoryresponse in the walls of arteries, in large part to the deposition of lipoproteins (plasma proteins that carry cholesterol and triglycerides). It is commonly referred to as a "hardening" or "furring" of the arteries. It is caused by the formation of multiple plaques within the arteries. Atherosclerosis causes two main problems. First, the atheromatous plaques, though long compensated for by artery enlargement, eventually lead to plaque ruptures and stenosis (narrowing) of the artery and, therefore, an insufficient blood supply to the organ it feeds. Alternatively, if the compensating artery enlargement process is excessive, then a net aneurysm results. The complications of atherosclerosis are chronic, slowly progressing and cumulative.
[0063] In some other embodiments, the invention provides therapeutic methods for inhibiting or ameliorating aberrant TLR4 signaling activities or undesired immune responses in subjects suffering from ischemia-reperfusion injuries (e.g., injuries to the heart, lung, liver, brain and other organs), and cardiac dysfunctions such as myocardial infarction and heart failure. The involvement of TLR4 signaling in ischemiareperfusion injuries is well established. For example, TLR4 signaling pathway has been shown to be associated with ischemia-reperfusion injuries in the lung (Shimamoto et al., Ann Thorac Surg. 82:2017-23, 2006), ischemia-reperfusion injuries in the liver (Wu et al., Hepatobiliary Pancreat. Dis. Int. 3:250-3, 2004), and ischemia injuries in the brain and stroke (Cao et al., Biochem. Biophys. Res. Commun. 353:509-14, 2007; and Caso et al., Circulation 115: 1599-608, 2007). TLR4 signaling pathway is also involved in cardiac ischemia-reperfusion injury (Staple et al., Eur J Heart Fail. 8:665-72, 2006; and Sakata et al., Am J Physiol. Heart Circ. Physiol. 292:H503-9, 2007).VI. Pharmaceutical compositions and methods of administration
[0064] The synthetic TLR4 antagonist peptides (e.g., SEQ ID NO: 1) and the other therapeutic agents disclosed herein, as well as polynucleotides encoding the peptides or derivative agents (e.g., mRNA or expression vectors), can be administered directly to subjects in need of treatment. However, these therapeutic compounds are preferable administered to the subjects in pharmaceutical compositions which comprise the TLR4 antagonist and / or other active agents along with a pharmaceutically acceptable carrier, diluent or excipient in unit dosage form. Accordingly, the invention provides pharmaceutical compositions comprising one or more of the synthetic TLR4 antagonist peptides disclosed herein. The invention also provides a use of these TLR4 antagonistsin the preparation of pharmaceutical compositions or medicaments for treating the above-described diseases or medical disorders wherein undesired signaling activities or responses mediated by TLR4 are present.
[0065] Pharmaceutically acceptable carriers are agents which are not biologically or otherwise undesirable. These agents can be administered to a subject along with a synthetic TLR4 antagonist peptide without causing any undesirable biological effects or interacting in a deleterious manner with any of the components of the pharmaceutical composition. The compositions can additionally contain other therapeutic agents that are suitable for treating or preventing aberrant TLR4 signaling activities or undesired immune response. Pharmaceutically carriers enhance or stabilize the composition or facilitate preparation of the composition. Pharmaceutically acceptable carriers include solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. The pharmaceutically acceptable carrier employed should be suitable for various routes of administration described herein. Additional guidance for selecting appropriate pharmaceutically acceptable carriers is provided in the art, e.g., Remington: The Science and Practice of Pharmacy, Mack Publishing Co., 20thed., 2000.
[0066] A pharmaceutical composition containing a synthetic TLR4 antagonist peptide or derivative compound described herein and / or other therapeutic agents can be administered by a variety of methods known in the art. The routes and / or modes of administration vary depending upon the desired results. Depending on the route of administration, the active therapeutic agent may be coated in a material to protect the compound from the action of acids and other natural conditions that may inactivate the agent. Conventional pharmaceutical practice may be employed to provide suitable formulations to administer such compositions to subjects. Any appropriate route of administration may be employed, for example, but not limited to, intravenous, parenteral, transcutaneous, subcutaneous, intramuscular, intracranial, intraorbital, intraventricular, intracapsular, intraspinal or oral administration. Depending on the specific conditions of the subject to be treated, either systemic or localized delivery of the therapeutic agents may be used in the treatment.
[0067] In some embodiments, local administration of TLR4 antagonists is desired in order to achieve the intended therapeutic effect. Many methods of localized delivery of therapeutic agents or formulations can be used in the practice of the invention. Forexample, local administration of a TLR4 antagonist to the desired cardiac muscle in a subject can be accomplished by a percutaneous route, by therapeutic cardiac catheterization, by intrapericardial injection or infusion, or by direct intracardiac muscle injection. Suitable methods also include any other routes which allow the therapeutic agent to be applied locally to the heart. For example, the therapeutic agent may be applied from the blood stream, by being placed directly in the heart through the coronary arteries or veins onto the heart surface, or through the ventricular or atrial walls and onto the heart surface. The therapeutic agent may also be applied through direct application during extensive surgical field exposure, or through direct application during minimally invasive exposure, e.g., through a pericardial window or heart port.
[0068] Pharmaceutical compositions of the invention can be prepared in accordance with methods well known and routinely practiced in the art. See, e.g., Remington: The Science and Practice of Pharmacy, Mack Publishing Co., 20thed., 2000; and Sustained and Controlled Release Drug Delivery Systems, J.R. Robinson, ed., Marcel Dekker, Inc., New York, 1978. Pharmaceutical compositions are preferably manufactured under GMP conditions. Formulations for parenteral administration may, for example, contain excipients, sterile water, or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated napthalenes. Biocompatible, biodegradable lactide polymer, lactide / glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compounds. Other potentially useful parenteral delivery systems for molecules of the invention include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation may contain excipients, for example, lactose, or may be aqueous solutions containing, e.g., polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel.
[0069] The TLR4 antagonists for use in the methods of the invention should be administered to a subject in an amount that is sufficient to achieve the desired therapeutic effect (e.g., eliminating or ameliorating symptoms associated with undesired immune responses) in a subject in need thereof. Typically, a therapeutically effective dose or efficacious dose of the TLR4 antagonist is employed in the pharmaceutical compositions of the invention. Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention can be variedso as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular subject, composition, and mode of administration, without being toxic to the subject. The selected dosage level depends upon a variety of pharmacokinetic factors including the activity of the particular employed composition, the route of administration, the time of administration, and the rate of excretion of the particular compound being employed. It also depends on the duration of the treatment, other drugs, compounds and / or materials used in combination with the particular compositions employed, the age, gender, weight, condition, general health and prior medical history of the subject being treated, and like factors. Methods for determining optimal dosages are described in the art, e.g., Remington: The Science and Practice of Pharmacy, Mack Publishing Co., 20thed., 2000. Typically, a pharmaceutically effective dosage would be between about 0.001 and 100 mg / kg body weight of the subject to be treated.
[0070] The synthetic TLR4 antagonist peptides and other therapeutic regimens described herein are usually administered to the subjects on multiple occasions.Intervals between single dosages can be daily, weekly, monthly or yearly. Intervals can also be irregular as indicated by measuring blood levels of the synthetic TLR4 antagonist peptides and the other therapeutic agents used in the subject. In some methods, dosage is adjusted to achieve a plasma compound concentration of 1-1000 pg / ml, and in some methods 25-300 pg / ml or 10-100 pg / ml. Alternatively, the therapeutic agents can be administered as a sustained release formulation, in which case less frequent administration is required. Dosage and frequency vary depending on the half-life of the synthetic TLR4 antagonist peptide and the other drugs in the subject. The dosage and frequency of administration can vary depending on whether the treatment is prophylactic or therapeutic. In prophylactic applications, a relatively low dosage is administered at relatively infrequent intervals over a long period of time. Some subjects may continue to receive treatment for the rest of their lives. In therapeutic applications, a relatively high dosage at relatively short intervals is sometimes required until progression of the disease is reduced or terminated, and preferably until the subject shows partial or complete amelioration of symptoms of disease. Thereafter, the subject can be administered a prophylactic regime
[0071] The invention also provides kits for carrying out the therapeutic applications disclosed herein. For example, the invention provides therapeutic kits for treating anyof the above-described diseases or disorders that are mediated by aberrant TLR4-signaling (e.g., sepsis). The therapeutic kits of the invention typically comprise as active agent one or more of the TLR4-targeting peptides or derivative compounds. The kits can optionally contain suitable pharmaceutically acceptable carriers or excipients for administering the active agents as described above. Other reagents that can be included in the kits include antioxidants, vitamins, minerals, proteins, fats, and carbohydrates. The therapeutic kits can further include packaging material for packaging the reagents and a notification in or on the packaging material. The kits can additionally include appropriate instructions for use and labels indicating the intended use of the contents of the kit. The instructions can be present on any written material or recorded material supplied on or with the kit or which otherwise accompanies the kit.EXAMPLES
[0072] The following examples are provided to further illustrate the invention but not to limit its scope. Other variants of the invention will be readily apparent to one of ordinary skill in the art and are encompassed by the appended claims.Example 1 Oligomerization of TLR4 TM domain in cellular context
[0073] We first evaluated the capacity for the TLR4 TM domain to oligomerization in a cellular context by assessing its relevance in the lipid bilayer of mammalian cells. To quantify these interactions, we adapted a split-enzyme cell-based assay, fusing TLR4-eGFP or its TM sequence to either the smBit or IgBit component of NanoLuc. Proximity-induced enzyme complementation generated a luminescent signal upon substrate addition, serving as a direct readout of protein-protein interactions (PPIs). To normalize for expression levels, we then introduce a competitive HiBit peptide, which displaces smBit binding and provides an internal reference. Widefield microscopy confirmed robust plasma membrane localization of TLR4-eGFP and TM constructs in 293T cells.
[0074] Across three biological replicates, TLR4-eGFP and TM constructs exhibited significantly higher (>100 fold, p < 0.005) normalized luminescence than the negative control (eVgL, a non-interacting synthetic design). Both TLR4-eGFP and TM selfinteractions also exceeded heterooligomer interactions with CD8a-TMJM, a promiscuous receptor used as a non-specific interaction control (p < 0.005 and p < 0.05,respectively). These findings establish a physiologically relevant molecular interface within the membrane, independent of chemical agonists or antagonists, presenting a new opportunity for tuning TLR4 signaling mechanisms via the membrane spanning regions.Example 2 De novo computational design of synthetic peptides that target TLR4
[0075] We then reasoned that the TLR4 transmembrane (TM) helix presents malleable surfaces for engineering synthetic protein-protein interactions. Targeting TLR4 in this manner also requires tackling an underlying fundamental challenge in membrane protein design: can protein-protein interactions within the membrane be encoded for binding primarily apolar single-span TM domains in a sequence-specific manner, particularly that TLR4’s dimerization interface is unknown and lacks an apparent motif sequence.
[0076] Previous computational efforts to design TM adaptors have relied on canonical interaction motifs (G-X-G, small-X-small), experimentally derived structural templates, or endogenously interacting sequences as starting scaffolds. Here, we expand and implement a de novo computational design method to develop synthetic peptides that target TLR4 independently of the structural or sequence context of the native interface. To guide design, we predicted homodimeric TLR4 TM complexes using AlphaFol d2 multimer, an evolutionary based deep learning model for structural prediction, and TMHop, a Rosetta physics-based fold-and-dock algorithm including a lipophilicity term for predicted transmembrane helix-helix interactions. The inventors selected three hypothetical models and rationalized their use as practical starting structures based on of their high interfacial interface surface area, potential for high contact density knobs-in-holes packing or stabilizing polar interactions, and principally that their different geometries enabled design models to cover distinct helix surfaces of TLR4’s TM span. Using the Rosetta membrane framework, we fixed one chain of the backbone model with the native TLR4 TM sequence and designed the other chain as the synthetic adaptor peptide using a set of membrane-compatible amino acids. Over three design rounds, generating 800 models per round, we eliminated amino acid choices at specific positions which consistently led to steric clashes or unfavorable rotamers. Designs were first filtered using a combinatorial threshold of a packing score and predicted interface energies. We then selected designs maximizing the favorablefeatures of hydrogen bonds between chains and the number of tight knobs into hole sidechain packing interactions. After selecting the set of de novo sequences, the final design step diversified the amino acids on each design’s lipid-facing surface to reflect the natural distribution of amino acids and removed potential self-interaction sequence patterns (Table 1). Interestingly, AlphaFold3 failed to accurately re-predict our design models. We then opted to use molecular dynamics simulations of 500 ns in model POPC membranes as an additional validation stage, wherein we determined 9 designs which form stable complexes with a TLR4 TM domain in silico that motivated biochemical characterization in cells. Altogether, this computational pipeline enables the rapid and accurate design of transmembrane interactors, robustly generating realistic TM-TM models that are stable in silico.Table 1. De novo designed transmembrane peptide sequencesExample 3 The peptides target and co-localize with TLR4 TM domain in cell membrane
[0077] To assess whether de novo peptides target the TLR4 TM domain and colocalize in mammalian cell membranes, we adapted the NanoBit split-enzyme assay to evaluate protein-protein interactions (Figure 1, panel A). We selected the minimalTLR4 TMJM fragment as the SmBit-tagged “Target” due to its favorable expression and performance in this assay. When tested against itself, the TMJM construct (SmBit-tagged “Target” co-expressed with LgBit-tagged “Binder”) exhibited a > 100-fold increase in split-enzyme complementation compared to the non-interacting negative control (eVgL LgBit-tagged protein), establishing a clear benchmark for positive interactions. Additionally, the normalized luminescence for self-interacting TMJM constructs was 2.2 ± 0.3-fold higher than that of TMJM paired with a non-specific control (CD8a, a promiscuous receptor). In comparison, self-interactions of TLR4-eGFP-SmBit and TM-SmBit were only and average 2.0 ± 0.5-fold and 1.8 ± 0.3-fold higher than their interactions with CD8a-LgBit, respectively. These results indicate that TMJM provides the more robust and optimal dynamic range for assessing the interaction potential of designed constructs compared to full-length TLR4-eGFP or minimal TM as the “Target.”
[0078] Following transient co-transfection of each designed TM protein with the TLR4 TMJM construct in HEK293T cells, widefield fluorescence microscopy confirmed robust expression and plasma membrane localization of the de novo designs (Figure 1, panel C). Since we performed Flag-tag immunostaining without membrane permeabilization, we conclude that the constructs predominantly insert in a type I orientation, supporting their potential to interact with TLR4 as designed and in a physiologically relevant manner. When tested against the TMJM target, all nine designs exhibited higher normalized luminescence than CD8a (Figure 1, panel B). Notably, Design 1 and Design 6 demonstrated exceptionally high interaction potential, with 65±10% and 99 ± 22% increases in normalized luminescence compared to the positive control, self-interacting TMJM. These results identify Designs 1 and 6 as lead anti-TLR4 TM protein candidates.
[0079] Design 1 was derived from an initial backbone geometry predicted by TMHop. Its interface features 12 tightly packed knobs-into-holes interactions and a single core polar residue, threonine, which forms a hydrogen bond with its own backbone atoms in the preceding helical turn. Consequently, Design 1 primarily relies on van der Waals interactions from apolar residues for stability (Figure 2, panel A). In contrast, Design 6 was built using an AlphaFol d2-multimer-predicted backbone geometry (Figure 2, panel B). The Design 6 model suggests that interface stabilization is achieved through a combination of hydrogen bonding and apolar packing: a predictedinterchain hydrogen bond between TLR4 TM Ser637 and Design 6 Thrl3, along with eight knobs-into-holes interactions distributed along the interface (Figure 2, panel C).Example 4 The peptides target TLR4 in a sequence specific manner
[0080] To establish the sequence specificity of these lead anti-TLR4 TM proteins, we generated modified constructs with scrambled the primary sequences for the TM span of designs assayed interactions by nanobit. The scrambled Designs 1 and 6 exhibit consistently lower luminescence signal upon co-expression with TL4-TMJM, relative to the non-scrambled parent TM proteins (2.5 + / - 0.5 fold-change with p = 0.002 and 1.8 + / - 0.4 fold-change with p=0.045), exhibiting PPI signal similar to that of the high-expressing non-specific control protein CD8a (Figure 2, panel D). These results support that these computationally designed proteins target TLR4 is sequence specific, ruling out that is co-localization due simply due to their TM length, amino acid composition (i.e., being inherently greasy), or overcrowding in restricted bilayer spaces (i.e., trafficking to similar membrane microdomains). Sequence specific interaction with TLR4 TM domain through a computationally designed de novo protein demonstrates how molecular recognition is encodable in the bilayer without canonical interfaces and that TRL4 TM domains present tunable targeting surfaces.
[0081] We also evaluated the off-target interaction potential for Design 1 and Design 6 to determine if the designed targeting molecules would form complexes with the TLR4 target receptor more readily than alternate membrane proteins in the membrane. We measured the interaction potential for Designs 1, 6, and TMJM for a panel of endogenous single or multi-pass transmembrane immune receptors with a similar nanobit experiment. For all receptors in our panel except for muOpiod receptor, the designed peptides displayed lower or insignificantly more normalized luminesce than the non-specific CD8alpha binder control (Figure 2, panel E). Thus, we preliminarily established our de novo designs are a unique molecular tool with TLR4 targeting capacity and minimal off-target interactions against targeting other proteins that reside the lipid bilayer.Example 5 The peptides inhibit TLR4 signaling
[0082] The successful development of native and synthetic molecular targeting tools against the TLR4 transmembrane (TMJM) domain prompted us to evaluate theirability to interact with full-length receptor target and in turn manipulate the crossmembrane signaling mechanism of TLR4. Ultimately, we aimed to assess whether the TLR4’s TM native interactions and inter-domain geometry is crucial for its long-range conformational coupling for cross-membrane signal activation. We reasoned that the native TMJM protein could elicit competing protein-protein interaction in the membrane would disrupt formation of the active receptor dimeric complex and inhibit NF-KB signaling downstream of LPS-stimulated TLR4 via lowering overall efficacy or shifting EC50 (Figure 3, panel A). To test this hypothesis, we used a colorimetric assay in a reporter cell line expressing NF-KB-inducible secreted embryonic alkaline phosphatase, along with co-receptors MD2 and CD14.
[0083] In this system, TLR4-GFP was activated 63.7±3.7% above basal levels with 10 pg / mL LPS when co-transfected with pcDNA control plasmid (Figure 3, panel C). The LPS induced activity of TLR4-eGFP with plasmid DNA delivery of the isolated TMJM fused to IgBit was only 22.5±12.8% above basal levels, meaning a 41.2±11.7% reduction in max signaling capacity. Since TMJM-mediated inhibition correlated with a measurable protein-protein interaction, this result underscores the role of native TLR4 cross-membrane interactions in receptor activation and establishes TLR TM fragments as dominant negative inhibitor well suited to probing membrane-spanning mechanisms.
[0084] We then evaluated the ability for synthetic designs to hinder TLR4 activation through interaction with full-length receptors in mammalian cells. We measured the effect of Design 6 fused to IgBit on TLR4-eGFP activity and observed a minimal 18.2±6.0% increase in activity above basal with LPS agonism (46.7±3.0% reduction from max signaling capacity). In contrast, its scrambled variant (Design 6 Scrambled) slightly increased TLR4-eGFP max signaling capacity by 3.54±9.1%, confirming that Design 6’s inhibitory effect is sequence-specific and dependent on targeted protein-protein interactions with the TMJM region of TLR4 (Figure 3, panel C). Importantly, there was not a large variability in TM targeting protein expression levels and basal activity was not significantly different across each challenged condition. To investigate the mechanism of inhibition, we then measured an LPS dosedependent activation curve for unchallenged or Design 6 challenged TLR4 activity. Design 6 reduced the maximal response but did not shift the EC50 value of LPS (Figure 3, panel B), supporting a model where native and synthetic transmembraneprotein sterically blocks the active receptor conformation to prevent downstream signaling.Example 6 Additional studies to examine TLR4-inhibiting activities of the peptides
[0085] We further demonstrated Design 6 also presents a dose-dependent inhibition response. HiBit luminescence served a metric to quantify the amount of Design 6 fused to largeBit in cells and affirms that increasing DNA amounts boosts total protein amount of Design 6 in each condition (Figure 4, panel B). Increased concentrations of Design 6 in cells resulted in increased inhibition activity also with a sigmoid like curve (Figure 4, panel D), while total TLR4 levels remained unaffected (Figure 4, panel C). These findings establish the sequence and dose dependent bioactivity of this peptide. This data also supports a mechanistic model where molecular targeting is synthetically encoded to intervene with native protein-protein interactions in the bilayer and disrupt receptor activity.
[0086] Interestingly, delivering Design 1 as plasmid DNA with IgBit fused displayed moderate inhibition, reducing max TLR4-eGFP activity by 35.1±7.4%, but lacked sequence-specific bioactivity. Although Design 1 Scrambled did not interact with the TLR4 TM in our protein-protein interaction assay, it still reduced max signaling capacity for TLR4-eGFP by 26.6±10.9% (Figure 3, panel C). This result suggests that Design 1 and Design 1 Scrambled may operate through a non-specific inhibition mechanism, rather than direct modulation of TLR4 structure and activity.
[0087] To confirm the interaction between TMJM and Design 6 in vitro, we captured a 2D NMR spectra of the TMJM-Design 6 interaction, wherein the 15N labelled spectra of a minimal TM-JM TLR4 alone peptide in DPC micelles is found to have distinct chemical shift perturbations in its 1H-15N HSQC spectra. These chemical shift perturbations suggest a stable and directly inter-atomic complex between TLR4 and Design 6 in model membranes. To investigate the direct interaction with the TM segment of TLR4 in vitro, we measured the solution NMR spectra of an U-15N TLR4-TMJM protein fragment with or without the presence of Design 6 as a minimal unlabeled TM peptide in2H-DPC micelles. We first explored the detergent-dependent self-interaction of this TLR4 TMJM fragment alone, varying DPC molar ratio to protein at 600x, 180x, and 60x. The TLR4 fragment exhibits chemical shift perturbations and broadening in itsJH-15N HSQC spectra for between 600x and 180x,indicative of likely homo-dimerization as seen previously (Mineev et al., Sci Rep 2017, 7, 6864), with apparent fast exchange. At 60x, (~1 protein per micelle on average, nearcrowding), TLR4 TMJM peaks further broaden, and some additional shifts occur but often in directions distinct from those perturbations between 600x and 180x, indicating mixtures of additional higher-order homo-assemblies, also seen previously. When TLR4 TMJM at 180x is reconstituted with 2 equivalents of Design-6, the spectra is broadly perturbed in fast-exchange relative to TLR4-TMJM’s spectra alone at 180x (likely homo-dimeric conditions) or at 600x (likely monomeric conditions). Design-6 induces a unique chemical environment for TLR-TMJM indicative of a direct complex stable to the 45° C and zwitterionic detergent micelle conditions. Given Design 6 does not induce further resonance broadening than TLR4-TMJM alone at 180x, and rather sharpens resonances, we believe the distinct perturbations are indicative of a unique hetero-dimeric complex rather than Design 6 binding the homodimer. Likewise, based on distinct chemical shift perturbation directions, formation of the Design 6-TMJM complex appears to be competitive with the homo-dimerization, which might indicate that Design 6 binds the TLR4 at a helix surface which is overlapping and mutually exclusive with its homo-dimerization interface.
[0088] Collectively, these findings demonstrate that both native and synthetic transmembrane-targeting peptides can modulate TLR4 activation by disrupting its TM-mediated cross-membrane protein interactions and signaling. By leveraging de novo design to encode sequence-specific interactions within the bilayer, we confirmed designed proteins in-cell and in vitro complex formation with the TLR4 TM domain. This expands protein design capability and presents a versatile blueprint for engineering targeted modulators that intervene in receptor activation by selectively competing with native TM-driven dimerization.Example 7 Some exemplified protocols
[0089] Cloning: All expression constructs were cloned into pcDNA3.1 using Gibson assembly. A full-length TLR4-eGFP fusion construct was generated with a flexible linker connecting it to the smallBit enzyme fragment for use in the NanoBit assay. For NanoBit assay target constructs involving minimal membrane-spanning regions, the design included: an influenza signal sequence (ssHA), an N-terminal Flag tag (the 3x HA epitope), the innTag soluble domain, a polar linker, the transmembrane(TM) or TM + juxtamembrane (JM) domain of TLR4 (as defined in UniProt), linkers flanking an HA tag, and a C-terminal smallBit fragment on the intracellular side.Binder constructs shared the same design as target constructs, with the exception that the innTag domain was excluded and the smallBit fragment was replaced with the largeBit enzyme component. All de novo designs and control binder TM sequences were synthesized as eBlocks (IDT).
[0090] Receptor expression constructs for functional assays consisted of full-length TLR4 fused to eGFP, linked via a flexible linker to a TEV protease site and TwinStrep tag at the C-terminus. This construct was also assembled via Gibson assembly using gBlocks (IDT). The same binder constructs used in the NanoBit assay were also employed as challenge peptides in the functional assays. For co-immunoprecipitation (co-IP) assays, either the HA or Flag tag was omitted from constructs to prevent redundancy in staining between bait and co-eluted proteins.
[0091] Immunostaining: Human embryonic kidney 293T cells were plated onto PDL coated, clear flat bottom 48-well plates with 1.8xl05cells per well. The same day as seeding, cells were transfected with 500 ng of DNA for constructs used in NanoBit or functional assays with Lipofectamine3000. Cells were first fixed with 4% paraformaldehyde for 10 minutes at room temperature. After washing three times with cold DPBS for 5 minutes, cells were incubated in a blocking buffer consisting of 1% bovine serum albumin (BSA) and 0.3 M glycine (22.52 mg / mL) in phosphate-buffered saline (PBS) for 1 hour at room temperature to prevent nonspecific antibody binding. Cells then incubated with primary antibody diluted (Flag M2, 1:300 dilution in 1% BSA in PBS) for 2 hours at room temperature or overnight at 4°C with gentle agitation. After primary incubation, cells were washed three times with PBS for 5 minutes each at room temperature. Secondary antibody incubation was performed using a 1 : 1000 dilution in 1% BSA in PBS for 1 hour at room temperature in the dark. Following incubation, the antibody solution was decanted, and cells were washed three times with PBS for 5 minutes each in the dark. For nuclear counterstaining, cells were incubated with Hoechst dye at a final concentration of 0.1-1 pg / mL for 5 minutes. The Hoechst stock solution was used at a 1 : 1000 dilution.
[0092] Cells were imaged at 20x long working distance magnification on Nikon Ti2-E Inverted Motorized Microscope equipped with SPECTRA III Light Source and Photometries IRIS 15 sCMOS Camera. Images were acquired using NIS-Elementssoftware and analyzed using Fiji for contrast and brightness adjustments. The setting for each fluorophore is described in the table below.
[0093] Structural Predictions: Initial models of TLR4 TM dimers were generated from AlphaFol d2 ColabFold notebook using the alphaFol d2 multimer v2 model and no templating. TMHop was used to predict additional models of TLR4 TM homodimers. Here, the central core sequence of TLR4 TM domain was used as input, and two idealized helices were aligned to the predicted dimer core to generate a full TM homodimer.
[0094] Molecular Dynamics: All molecular dynamics (MD) simulations were performed using GROMACS version 2020.3 with the CHARMM36 force field, modified to include updated WYF parameters for aromatic residue representation. Initial transmembrane dimer models were generated using Rosetta and oriented within a membrane bilayer using the OPM (Orientations of Proteins in Membranes) database. The protein-membrane system was built with a defined ratio of 40% POPC, 35% POPE, and 25% cholesterol using the CHARMM-GUI membrane builder.
[0095] Following energy minimization, the system was equilibrated in three stages: NVT, NPT, and production MD. An initial 50 ps equilibration was performed under constant volume with a 1 fs time step. Position restraints were applied to the protein backbone (4000 kJ / mol / nm2), sidechains (2000 kJ / mol / nm2), and lipids (1000 kJ / mol / nm2). Dihedral restraints were also applied with a force constant of 1000 kJ / mol / nm2Temperature was maintained at 310 K using the velocity-rescaling (V-rescale) thermostat, with separate temperature coupling groups defined for protein, lipid, and solvent. Electrostatics were treated using the Particle Mesh Ewald (PME) method with a cutoff of 1.2 nm, and van der Waals interactions used a force-switch modifier between 1.0 and 1.2 nm. All bonds to hydrogen were constrained using the LINCS algorithm.
[0096] Subsequently, the system was equilibrated for 15 ns under constant pressure using a 2 fs time step. Position restraints were applied to Ca atoms only. Temperaturewas maintained at 310 K using the Berendsen thermostat (T = 1.0 ps), and pressure was coupled semi-isotropically at 1 bar using the Berendsen barostat (T = 5.0 ps, compressibility = 4.5 x IO5bar1)- Electrostatics, van der Waals, and constraint parameters remained consistent with the NVT phase.
[0097] Production simulations were performed for up to 1 microsecond using a 2 fs time step. Temperature was maintained at 310 K using the Nose-Hoover thermostat with independent coupling for protein, lipid, and solvent. Pressure was semi-isotropically coupled at 1 bar using the Parrinello-Rahman barostat (T = 5.0 ps, compressibility = 4.5 x IO5bar1). The Particle Mesh Ewald method was used for long-range electrostatics, and a force-switch modifier was applied to the van der Waals interactions between 1.0 and 1.2 nm. Center-of-mass motion was removed every 100 steps.
[0098] Root mean square deviation (RMSD) and root mean square fluctuation (RMSF) analyses were performed using VMD (Visual Molecular Dynamics) software.
[0099] Protein-Protein Interaction Assay - NanoBit: Human embryonic kidney 293T cells were originally obtained from Invivogen. DNA was isolated using Qiagen or Zymo miniprep kits and diluted to standardized concentrations prior to transfection. Cells were co-transfected with 30 ng of target (smallBit constructs) and 20 ng of binder (largeBit constructs) using Lipofectamine3000. At the time of co-transfection, cells were seeded into PDL-coated white opaque, flat bottom 96-well plates. Eighteen to twenty-four hours after seeding, media was replaced with CCE-independent DMEM. Luminescence was measured for each well with the Tecan Spark plate reader using a 250 ms integration time and no attenuation after adding Furimazine to each well. HiBit peptide was then added into cells after permeabilizing with Digiton for a secondary luminescence measurement to quantify the amount of largeBit binder in each condition. Tecan Spark setting were slightly different for this read, using a 250 ms integration time and OD1 attenuation, and reads were acquired every 3 minutes until luminescence values across the plate plateaued and began to drop. Normalized luminescence was calculated by dividing the initial luminescence (RLU) by the highest recorded values for HiBit supplemented luminescence (RLU) of each condition. Three biological replicates were performed for every interaction measured, and technical replicates were performed in triplicate within each experiment.
[0100] Statistical analysis was performed using GraphPad Prism software. For comparisons involving multiple conditions, an Analysis of Variance (ANOVA) was conducted, where the mean of each experimental condition was compared to the mean of a single control group to identify significant interactions between binders and targets. In cases where only two conditions were compared, an unpaired two-tailed t-test was used to assess differences between the two groups. Statistical significance was considered at < 0.05.
[0101] NFKB Seap Functional Assay: Human embryonic kidney 293T Blue (HEK-Blue) cells were originally obtained from Invivogen (now discontinued). Reporter cells were maintained in DMEM complete medium, which consisted of DMEM supplemented with 10% FBS, 4 mM L-glutamine, 20 mM HEPES (pH 7.3), 1 x penicillin / streptomycin (P-S), and selective antibiotics according to the manufacturer’s recommendations. TLR4-eGFP constructs (200 ng per well) were co-transfected with either control or designed peptides (100 ng per well) using Lipofectamine 3000 (cat. No.). Co-transfected cells were seeded into PDL-coated, 96-well, black-walled, clear, flat-bottom plates with 5.0 x io4cells per well in DMEM complete medium. Eighteen to twenty-four hours after transfection and seeding, cells were treated with LPS-EB (Invivogen) diluted in ddEEO. After an additional 18-24 hours, an aliquot of cell culture supernatant was added to Quanti-Blue SEAP detection medium. Following a 1-6 hour incubation at 37 °C, SEAP reporter activity was measured using optical density on a Tecan Spark plate reader (655 nm, 50 ms settle time, with a filled 3x3 circular read pattern and 1000 pm border size).TLR4-eGFP expression levels were quantified using fluorescence measurements on the Tecan Spark plate reader. After aspirating the media, 30 pL of DPBS was added to each well. Readings were performed using topread mode with the following settings: 485 nm excitation (20 nm bandwidth), 520 nm emission (10 nm bandwidth), 20 flashes, optimal gain, dichroic 510 mirror, and 16 reads per well in a 4x4 circular read pattern with 500 pm border size. To quantify expression of control or designed binders, cells were resuspended in 100 pL of CO2-independent DMEM. Digitonin was added to permeabilize cells, followed by the addition of Furimazine and HiBiT reagents. Luminescence was measured for each well using the Tecan Spark plate reader with a 250 ms integration time and no attenuation. Three biological replicates were performed for every interaction measured, and technical replicates were performed in triplicate within each experiment. Statisticalanalysis was performed using GraphPad Prism software. An unpaired two-tailed t-test was used to assess differences between the two groups. Statistical significance was considered at < 0.05.
[0102] Co-immunoprecipitation: HEK293T cells were cultured in PDL coated 15-cm dishes to achieve sufficient biomass and transfected with constructs encoding FLAG-tagged binder and 3xHA-tagged TMJM using Lipofectamine 3000 and P3000 reagents (Thermo Fisher) in OptiMEM (Gibco). Cells were harvested 22-24 hours post-transfection, washed with PBS, and pelleted at 4000 rpm for 5 minutes at room temperature.
[0103] Cell pellets were resuspended in ice-cold sonication buffer (20 mM HEPES, 50 mM NaCl, 10 mM KC1, 5 mM MgCE, 1 mM TCEP, and protease inhibitors) and sonicated using a tip sonicator. Lysates were cleared by centrifugation at 21,000 x g for 15 min at 4°C, and membranes were isolated by ultracentrifugation at 400,000 x g for 45 min at 4°C. Supernatants were collected (soluble fraction), and the pellet (membrane fraction) was solubilized in lysis buffer (20 mM HEPES, 75 mM NaCl, 5 mM CaCL, 5 mM MgCE, 1 mM TCEP, 10% glycerol, 1% DDM:CHS, protease inhibitors) for 20 min at 4°C with rotation.
[0104] Following solubilization, samples were incubated with anti-FLAG M2 magnetic beads (Sigma-Aldrich, 10 pL per sample, pre-washed with lx TBS) for 3 hours at 4°C with end-over-end rotation. Beads were washed three times with wash buffer (same as lysis buffer with 0.2-0.1% DDM:CHS), and bound complexes were eluted sequentially using 0.4 mg / mL 3x FLAG peptide in wash buffer (10-15 min incubations per elution).
[0105] Samples were mixed with 6x Laemmli buffer containing TCEP, kept at 4°C, and resolved via SDS-PAGE using Bio-Rad stain-free gels. Gels were run at 250 V for 30 min and transferred to PVDF membranes (Bio-Rad) using standard semi-dry conditions (mini: 1.0 A, 5 min; midi: 2.0 A, 5 min). Membranes were blocked with 5% BSA in TBST and probed overnight at 4°C with anti-FLAG M2 (mouse), HA-647 (BioLegend), and Alexa Fluor 555-conjugated anti-mouse secondary antibodies. Blots were washed in TBST and imaged using appropriate fluorescence channels (555 for FLAG and 647 for HA).
[0106] Solution NMR: TLR4 fragment sequence representing TMJM fused at its n-terminus with a 6X His tag and thrombin cleavage site was expressed from pET-28a(+)in BL21(DE3) cells in M9 minimal medium supplemented with 0.5 g[15N]NH4Ch (Cambridge Isotopes) and 0.2 g of isotope-enriched ISOGROW (Sigma) per liter of culture with 50 pg / mL kanamycin. Cells were induced with 0.5 mM IPTG at an optical density of 0.8 followed by overnight growth at 30 °C.
[0107] Pelleted cells were suspended in a lysis buffer: 8 M urea, 0.5 mM EDTA, 50 mM sodium phosphate pH 8.3, supplemented sequentially with 0.2 mg / mL lysozyme, 5 mM MgC12, 1 U / mL benzonase, and 0.5%(w / v) SDS. Lysate was sonicated and rotated before centrifugation (30min, 14500RPM, 4C). Supernatant of the centrifuged Lysate was incubated with Ni-NTA agarose resin (HisPur, Thermo Fisher) overnight at RT with rotation for protein binding. Resin was washed with 10 times of 2 column volumes of detergent-free lysis buffer and then washed with 3 times of 2 column volumes of 25 mM imidazole detergent-free lysis buffer. To exchange the detergent from SDS to DPC, Resin was further washed with 4 times of 2 column volumes of 50mM imidazole 5mM DPC lysis buffer. Then His-TMJM is eluted in lysis buffer containing 8mM DPC and 200mM imidazol. Eluted His-TMJM was further polished by FPLC AnEx in Tris-HCl pH8.0, 4mM DPC, and a gradient of NaCl from OmM to 400mM. Fractions of AnEx were combined and concentrated by 10K Amicon. The concentrated samples were used in CME(Chloroform Methanol Extraction) to remove the detergent and the pelleted protein was reconstituted in HFIP to make a concentration known stock.
[0108] Synthesized Design6 peptides were purified by RP-HPLC using a C4 semiprep column (10-pm, 214TP, Vydac) using a linear gradient of solvent A (water, 0.05% TFA) and solvent B (60 / 30 / 9 / 0.9 / 0.1 isopropanol / acetonitrile / TFE / water / TFA).
[0109] Isotopically enriched His-TMJM fragments in HFIP stock solution of known concentration were combined with synthetic Anti-TLR4 Design6 peptides (HFIP) along with 2H-DPC(Cambridge), dried under a nitrogen gas stream and further dried under the vacuum. Samples were reconstituted in NMR buffer (45 mM HEPES pH 6.0, 50 mM NaCl, 0.5 mM EDTA, 5 mM DTT, 10% (v / v) D2O) and then sonicated, centrifuged, and transferred to a 3-mm Shigemi tube. Spectra of labeled His-TMJM fragments with and without CHAMP were recorded at 40 °C on a Bruker 800-MHz spectrometer with cryogenic triple-resonance probes: [JH-15N] Best TROSEY. Spectra were processed in NMRPipe Assignment and analysis were performed using Sparky.***
[0110] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to one of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
[0111] All publications, databases, GenBank sequences, patents, and patent applications cited in this specification are herein incorporated by reference as if each was specifically and individually indicated to be incorporated by reference.
Claims
WHAT IS CLAIMED IS:
1. A synthetic peptide that is capable of binding to human TLR4, comprising an amino acid sequence that is at least 90% identical to any one of the sequences set forth in SEQ ID NOs:l-9.
2. The synthetic peptide of claim 1, comprising an amino acid sequence that is a conservatively modified variant of any one of the sequences set forth in SEQ ID NOs: 1-9.
3. The synthetic peptide of claim 1, comprising an amino acid sequence that is at least 93% or at least 96% identical to any one of the sequences set forth in SEQ ID NOs: 1-9.
4. The synthetic peptide of claim 1, comprising an amino acid sequence that is identical to any one of the sequences set forth in SEQ ID NOs: 1-9 and 11-21.
5. The synthetic peptide of claim 1, which can inhibit TLR4 signaling.
6. The synthetic peptide of claim 5, comprising an amino acid sequence set forth in SEQ ID NO: 1 or 2, or a conservatively modified variant thereof.
7. A polynucleotide encoding the synthetic peptide of claim 1.
8. The polynucleotide of claim 7, which is a DNA or an mRNA.
9. A vector harboring the polynucleotide of claim 7.
10. The vector of claim 9, which is an AAV vector.
11. A compound comprising a TLR4-binding peptide that is conjugated to a carrier moiety, wherein the TLR4-binding peptide comprises an amino acid sequence that is at least 90% identical to any one of the sequences set forth in SEQ ID NOs: 1-9.
12. The compound of claim 11, wherein the carrier moiety is a carrier protein, an immunoglobulin, a Fc domain, a liposome, or a PEG molecule.
13. The compound of claim 11, wherein the TLR4-binding peptide comprises an amino acid sequence set forth in SEQ ID NO: 1 or 2, or a conservatively modified variant thereof.
14. A compound comprising dimerized or multimerized TLR4-binding peptides, wherein each of the TLR4-binding peptides comprises an amino acid sequence that is at least 90% identical to any one of the sequences set forth in SEQ ID NOs: 1-9.
15. The compound of claim 14, wherein the TLR4-binding peptides are attached by linker moieties.
16. The compound of claim 14, wherein the TLR4-binding peptides each comprises an amino acid sequence set forth in SEQ ID NO: 1 or 2, or a conservatively modified variant thereof.
17. The compound of claim 14, wherein the TLR4-binding peptides each comprises an amino acid sequence as shown in SEQ ID NO:1 or a conservatively modified variant thereof.
18. A method of inhibiting or suppressing Toll-like receptor 4 (TLR4) signaling activities in a subject, comprising administering to a subject suffering from undesired TLR4 signaling activities a pharmaceutical composition comprising a therapeutically effective amount of a synthetic TLR4 antagonist peptide, thereby inhibiting or suppressing signaling activities of a Toll-like receptor 4 (TLR4) in the subject; wherein the synthetic TLR4 antagonist peptide comprises an amino acid sequence set forth in SEQ ID NO: 1 or 2, or a conservatively modified variant thereof.
19. The method of claim 18, wherein the subject suffers from sepsis, a chronic inflammatory disorder, an ischemia-reperfusion injury, or a myocardial injury.
20. The method of claim 18, wherein the TLR4 antagonist peptide comprises an amino acid sequence as set forth in SEQ ID NO: 1.
21. The method of claim 18, wherein the TLR4 antagonist peptide is multimerized or is conjugated to a carrier moiety.
22. The method of claim 21, wherein the carrier moiety is a carrier protein, an immunoglobulin, a Fc domain, a PEG molecule, or a liposome.
